-
Entrectinib, sold
under the
brand name Rozlytrek, is an anti-cancer
medication used to
treat ROS1-positive non-small cell lung
cancer and NTRK fusion-positive...
- for
medical use
include Pembrolizumab, Larotrectinib, Selpercatinib,
Entrectinib, and Pralsetinib.
Pembrolizumab was
approved by the US Food and Drug...
-
counteract the
effects of Trk over-expression by
acting as a Trk inhibitor.
Entrectinib (formerly RXDX-101) is an
investigational drug
developed by Ignyta, Inc...
-
hepatitis C.
Rohypnol (flunitrazepam), for
severe insomnia.
Rozlytrek (
entrectinib), for ROS1-positive non-small cell lung
cancer and NTRK fusion-positive...
- den Buuse, 2020;
Pradhan et al., 2019;
Tejeda and Díaz-Guerra, 2017).
Entrectinib (formerly RXDX-101) is an
investigational drug
developed by Ignyta, Inc...
- L01EX11
Quizartinib L01EX12
Larotrectinib L01EX13
Gilteritinib L01EX14
Entrectinib L01EX15
Pexidartinib L01EX17
Capmatinib L01EX18
Avapritinib L01EX19 Ripretinib...
- can be
inhibited by crizotinib, lorlatinib, or
entrectinib;
overactive NTRK (<1% of NSCLC) by
entrectinib or larotrectinib;
active RET (around 1% of NSCLC)...
-
Infigratinib Pemigatinib Avapritinib Cabozantinib Capivasertib Capmatinib Entrectinib Gilteritinib Larotrectinib Lenvatinib Masitinib Midostaurin Nintedanib...
-
Kinase inhibitors:
Altiratinib AZD-6918 CE-245677 CH-7057288 DS-6051
Entrectinib GZ-389988 K252a
Larotrectinib Lestaurtinib Milciclib ONO-4474 ONO-5390556...
- lung
carcinoma (NSCLC). However, some
clinical trials (like
those for
entrectinib, DS-6051b, and TPX-0005)
accept patients with ROS1
cancer in any type...
